Skip to main content
. 2020 Jun 19;12(6):665. doi: 10.3390/v12060665

Figure 5.

Figure 5

Effects of dasatinib and bufalin on PBMCs treated with cART. Three samples of HIV-1-infected, latent PBMCs were treated with 2.5 nM and 0.5 µM of bufalin and dasatinib, respectively, prior to incubation at 37 °C for 2 h. EVs isolated via ultracentrifugation from each of the PBMCs prior to infection with HIV-1 (89.6) were added back to each of their respective PBMCs. The total ratio of cells to EVs was 1:5000. Cells were then harvested after 72 h of incubation at 37 °C. Total RNA was isolated and subjected to RT-qPCR from cell pellets for HIV-1 TAR (A) and genomic RNA (B). (C) Virions were concentrated from cell supernatant using NT86 and NT80/82 and rotated overnight at 4 °C. Samples were Western blotted for p24. Densitometry counts normalized to actin across all samples are shown for p24 (D). CEM and ACH2 WCE were used as a negative and positive control, respectively. Actin was used as a loading control. Student’s t-test compared untreated cells with cells treated with drugs. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Error bars, S.D.